Miranda Christianen

Miranda Christianen is a researcher at Erasmus MC in the Department of Radiotherapy, actively contributing to clinical and translational research in prostate cancer treatment. Her work focuses on high-dose-rate brachytherapy (HDR-BT), electromagnetic tracking, and hypofractionated radiation regimens. She collaborates extensively with a multidisciplinary team including experts in radiation oncology, medical physics, and urology.

Her research interests lie at the intersection of advanced radiotherapy techniques and clinical outcomes. She investigates prostate cancer treatment precision using electromagnetic tracking for real-time implant reconstruction and error detection during HDR-BT. Her work also explores ultra-hypofractionation and online adaptive robotic radiation therapy, aiming to improve patient outcomes while minimizing side effects such as urinary and bowel dysfunction.

The trend in her recent publications shows a strong emphasis on image-guided and adaptive radiotherapy, with a focus on technical innovation and clinical validation. Her studies frequently employ prospective cohort designs and advanced imaging modalities like transrectal ultrasonography and CT-based planning.

Miranda Christianen has not been publicly recognized with any listed scientific awards in the provided text.

She is involved in significant clinical research projects, particularly in developing and validating novel radiation delivery methods for high-risk prostate cancer. Her work is supported by collaborative grants, though specific funding sources are not mentioned. She contributes to both technical and clinical aspects of radiotherapy, working closely with teams in medical physics and radiation oncology.

She is part of a research network at Erasmus MC focused on improving the precision and safety of brachytherapy through real-time monitoring and adaptive planning technologies. This team integrates engineering solutions with clinical oncology to advance patient-specific treatment protocols.